AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26036623 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic Extracts (GE)
Number of subjects: 95
Study 26036623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 24229674 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated lumbrokinase capsules plus standard stroke treatment
Number of subjects: 310
Study 24229674 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke treatment
Number of subjects: 310
Study 21616282 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 2292
Study 21616282 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2292
Study 19666939 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of oral calcium supplement, daily, for 8 weeks
Number of subjects: 51
Study 19666939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16943106 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA)
Number of subjects: 180
Study 16943106 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral approach (TRF)
Number of subjects: 180
Study 15288159 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg body weight, maximum 200 mg, given over 20 min)
Number of subjects: 207
Study 15288159 — intervention group
Group type: COMPARATOR
Intervention: Ibutilide (1 mg or 0.01 mg/kg if less than 60 kg, infused over 10 min)
Number of subjects: 207
Study 15288159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Flecainide and Ibutilide)
Number of subjects: 207
Study 11288049 — intervention group
Group type: EXPERIMENTAL
Intervention: high‐vegetable, fruit, and nut diet (very‐high‐fiber, 55 g/1,000 kcal)
Number of subjects: 10
Study 9586411 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 18
Study 9586411 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist Control Ventilation (ACV)
Number of subjects: 18
Study 8307554 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (0.25 microgram/kg/min)
Number of subjects: 45
Study 8307554 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerine (1.5 micrograms/kg/min)
Number of subjects: 45
Study 8307554 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 45
Study 3709026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (2 mg)
Number of subjects: 0
Study 3709026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (4 mg)
Number of subjects: 0
Study 3709026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (2 or 4 mg)
Number of subjects: 0
Study 3709026 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 0
Study 31713941 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed extract (GSE) 300 mg/day
Number of subjects: 40
Study 31713941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29879777 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-step core stability exercise program for 8 weeks
Number of subjects: 36
Study 29879777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 26961367 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated model of care for botulinum toxin treatment
Number of subjects: 266
Study 26961367 — intervention group
Group type: COMPARATOR
Intervention: Standard model of care for botulinum toxin treatment
Number of subjects: 266
Study 25007723 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Total Hip Arthroplasty (DA‐THA)
Number of subjects: 54
Study 25007723 — intervention group
Group type: COMPARATOR
Intervention: Mini-Posterior Approach Total Hip Arthroplasty (MPA‐THA)
Number of subjects: 54
Study 22761191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual extract of rye grass for 6 months
Number of subjects: 24
Study 22761191 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 24
Study 20367777 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE5 inhibitors plus regular physical activity (≥3 hours/week)
Number of subjects: 60
Study 20367777 — intervention group
Group type: COMPARATOR
Intervention: PDE5 inhibitors alone
Number of subjects: 60
Study 20367777 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE5 inhibitors plus physical activity
Number of subjects: 60
Study 18560801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 502
Study 18560801 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 502
Study 18560801 — intervention group
Group type: COMPARATOR
Intervention: Rural environment
Number of subjects: 502
Study 16043199 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg.kg(‐1) day(‐1) caffeine intake (G3)
Number of subjects: 60
Study 16043199 — intervention group
Group type: COMPARATOR
Intervention: 0 mg.kg(‐1) day(‐1) caffeine intake (G0)
Number of subjects: 60
Study 16043199 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg.kg(‐1) day(‐1) caffeine intake (G6)
Number of subjects: 60
Study 11950104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (3 alcoholic drinks)
Number of subjects: 0
Study 11950104 — intervention group
Group type: COMPARATOR
Intervention: Control beverage consumption (3 control drinks)
Number of subjects: 0
Study 10027430 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 microg/d
Number of subjects: 347
Study 10027430 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-BDP 800 microg/d
Number of subjects: 347
Study 10027430 — intervention group
Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 347
Study 7673547 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-consequences curriculum
Number of subjects: 48
Study 7673547 — intervention group
Group type: EXPERIMENTAL
Intervention: Various approaches
Number of subjects: 48
Study 7673547 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive program with all 3 components
Number of subjects: 48
Study 7673547 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based tobacco use interventions
Number of subjects: 48
Study 2343720 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 2343720 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 0
Study 2343720 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 760698 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin administered subcutaneously
Number of subjects: 12
Study 760698 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin administered in the evening
Number of subjects: 12
Study 760698 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin
Number of subjects: 12
Study 29173086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) guidance for single-puncture arthrocentesis (SPA)
Number of subjects: 24
Study 29173086 — intervention group
Group type: COMPARATOR
Intervention: Single-puncture arthrocentesis (SPA) without US guidance
Number of subjects: 24
Study 29298634 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based nutrition education intervention using social cognitive theory (SCT) for 7 months
Number of subjects: 172
Study 25111539 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 2 mg/kg
Number of subjects: 12
Study 25111539 — intervention group
Group type: COMPARATOR
Intervention: neostigmine 70 μg/kg
Number of subjects: 12
Study 23292556 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping polyester and polylactic acid mesh (SGM)
Number of subjects: 96
Study 23292556 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene and poliglecaprone mesh fixed with four titanium staples (ST)
Number of subjects: 96
Study 21893621 — intervention group
Group type: COMPARATOR
Intervention: Gastric bypass (n = 31)
Number of subjects: 60
Study 21893621 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal switch (n = 29)
Number of subjects: 60
Study 21893621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 20047905 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis in addition to standard anticoagulation
Number of subjects: 0
Study 20047905 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulation
Number of subjects: 0
Study 17318498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamine supplementation (alanyl-glutamine) for 20 hours
Number of subjects: 12
Study 17318498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 17318498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamine supplementation (alanyl-glutamine)
Number of subjects: 12
Study 14749232 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 1 x 10(7) CFU/g each of Bifidobacterium lactis and Streptococcus thermophilus
Number of subjects: 118
Study 14749232 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 1 x 10(6) CFU/g each of Bifidobacterium lactis and Streptococcus thermophilus
Number of subjects: 118
Study 14749232 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented formula
Number of subjects: 118
Study 11373349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with ketoanalogs (n = 6)
Number of subjects: 12
Study 11373349 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet without ketoanalogs (n = 6)
Number of subjects: 12
Study 9005964 — intervention group
Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN) alone (n = 6)
Number of subjects: 12
Study 9005964 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN + recombinant human growth hormone (rGH) at a daily dose of 0.15 U x kg(‐1) x d(‐1) (n = 6)
Number of subjects: 12
Study 9005964 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PPN and PPN + rGH) during fed state
Number of subjects: 12
Study 9005964 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PPN and PPN + rGH)
Number of subjects: 12
Study 9005964 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN + rGH group
Number of subjects: 12
Study 9005964 — intervention group
Group type: COMPARATOR
Intervention: PPN group
Number of subjects: 12
Study 8435262 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (non-stress group)
Number of subjects: 30
Study 8435262 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (stress group)
Number of subjects: 30
Study 3299095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination amphotericin B and flucytosine for four weeks
Number of subjects: 194
Study 3299095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination amphotericin B and flucytosine for six weeks
Number of subjects: 194
Study 3299095 — intervention group
Group type: COMPARATOR
Intervention: Not randomized group (protocol not followed during initial four weeks)
Number of subjects: 194
Study 29351789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐OP (tobramycin and colistin sulphate)
Number of subjects: 966
Study 29351789 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 966
Study 27756037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic rosuvastatin (RSV)
Number of subjects: 53
Study 27756037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic pitavastatin (PTV)
Number of subjects: 53
Study 24142329 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) 150 mg kg(‐1) intravenously prior to incision, followed by 15 mg kg(‐1) h(‐1) infusion until 2 h after graft reperfusion
Number of subjects: 59
Study 24142329 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 59
Study 23578722 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP14 (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 40 mg/m² daily for 5 days, administered every 14 days)
Number of subjects: 602
Study 23578722 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP21 (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 40 mg/m² daily for 5 days, administered every 21 days)
Number of subjects: 602
Study 23578722 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP14
Number of subjects: 602
Study 23578722 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP21
Number of subjects: 602
Study 20053539 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (risperidone, olanzapine, quetiapine IR, ziprasidone, risperidone consta, aripiprazole, paliperidone, quetiapine XR)
Number of subjects: 7553
Study 20053539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7553
Study 20053539 — intervention group
Group type: COMPARATOR
Intervention: Active treatment vs Placebo
Number of subjects: 7553
Study 17965045 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive activities of daily living (ADL) activity programme
Number of subjects: 149
Study 17965045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 149
Study 16868539 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT) - cisplatin (50 mg m(‐2)), doxorubicin (45 mg m(‐2)), cyclophosphamide (600 mg m(‐2)) every 28 days for five cycles
Number of subjects: 345
Study 16868539 — intervention group
Group type: COMPARATOR
Intervention: External radiotherapy (RT) - 45‐50 Gy on a 5 days week(‐1) schedule
Number of subjects: 345
Study 12859554 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (5 treatments on the first day at 1-hour intervals)
Number of subjects: 30
Study 12859554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 treatments on the first day)
Number of subjects: 30
Study 12859554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Capsaicin and Placebo)
Number of subjects: 30
Study 12859554 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety data (Capsaicin and Placebo)
Number of subjects: 30
Study 10649197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic perfusion
Number of subjects: 291
Study 10649197 — intervention group
Group type: COMPARATOR
Intervention: Tepid/normothermic perfusion
Number of subjects: 291
Study 8878099 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 6
Study 8878099 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin with placebo
Number of subjects: 6
Study 8878099 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin with 10 mg flumazenil
Number of subjects: 6
Study 8878099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8878099 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil plus placebo
Number of subjects: 6
Study 1948589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 192
Study 1948589 — intervention group
Group type: COMPARATOR
Intervention: No cervical cerclage
Number of subjects: 192
Study 6481798 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A imagery scripts
Number of subjects: 20
Study 6481798 — intervention group
Group type: COMPARATOR
Intervention: Type A and Neutral imagery scripts
Number of subjects: 20
Study 6481798 — intervention group
Group type: COMPARATOR
Intervention: Structured Interview (SI)
Number of subjects: 20
Study 30535651 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg
Number of subjects: 200
Study 30535651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 27600184 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose added to fructose in solution
Number of subjects: 26
Study 27600184 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose added to fructans
Number of subjects: 26
Study 27600184 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose added to whole foods containing fructose
Number of subjects: 26
Study 25782985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (n=23)
Number of subjects: 48
Study 25782985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 48
Study 23402650 — intervention group
Group type: EXPERIMENTAL
Intervention: Collared silicone punctal plugs
Number of subjects: 30
Study 23402650 — intervention group
Group type: COMPARATOR
Intervention: Intracanalicular SmartPlugs
Number of subjects: 30
Study 20800509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 16
Study 20800509 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 16
Study 19438399 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g orally as a single dose)
Number of subjects: 398
Study 19438399 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg orally twice a day for 7 days)
Number of subjects: 398
Study 19438399 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 398
Study 19438399 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 398
Study 16705448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml ICG staining
Number of subjects: 13
Study 16705448 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/ml ICG staining
Number of subjects: 13
Study 16705448 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 13
Study 16705448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICG groups
Number of subjects: 13
Study 15476576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg intravenously administered 14 days before bed rest)
Number of subjects: 25
Study 15476576 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise (squats and heel raises for 30 minutes every 3 days)
Number of subjects: 25
Study 15476576 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 11241043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 81
Study 11241043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 9562008 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 to 8 mg/day)
Number of subjects: 77
Study 9562008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 to 50 mg/day) plus Amiloride (1.25 to 5 mg/day)
Number of subjects: 77
Study 8174299 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 0
Study 8174299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8174299 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 3107514 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl 10 mg/d
Number of subjects: 17
Study 3107514 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl 40 mg/d
Number of subjects: 17
Study 3107514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31389750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation (LLLI) applied to one of the two implants (940-nm wavelength, 0.50 ± 2 mW output power, 0.004 cm2 spot size; total delivered energy of 90 J in 3 sessions)
Number of subjects: 20
Study 31389750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLI applied)
Number of subjects: 20
Study 31389750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation (LLLI)
Number of subjects: 20
Study 28639128 — intervention group
Group type: EXPERIMENTAL
Intervention: 4L polyethylene glycol (4L-PEG)
Number of subjects: 109
Study 28639128 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L polyethylene glycol plus ascorbic acid (2L-PEG-Asc)
Number of subjects: 109
Study 25586095 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine HMGA1 levels in serous epithelial ovarian cancer patients
Number of subjects: 75
Study 25586095 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine HMGA1 levels in G3 ovarian cancer specimens
Number of subjects: 75
Study 25586095 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine HMGA1 detection
Number of subjects: 75
Study 25586095 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine HMGA1 combined with serum CA-125
Number of subjects: 75
Study 25586095 — intervention group
Group type: COMPARATOR
Intervention: Serum CA-125 levels
Number of subjects: 75
Study 23275474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation with three-dimensional mapping and circular mapping catheter
Number of subjects: 378
Study 23275474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing from within the PV
Number of subjects: 378
Study 22030858 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of pivmecillinam treatment
Number of subjects: 155
Study 22030858 — intervention group
Group type: COMPARATOR
Intervention: 3 days of pivmecillinam treatment
Number of subjects: 155
Study 22030858 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli causing persistence or relapse
Number of subjects: 155
Study 22030858 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of agn43a(CFT073) or agn43b(CFT073)
Number of subjects: 155
Study 22030858 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro biofilm formation
Number of subjects: 155
Study 18357655 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-matching foot-stepping exercise (TMFSE)
Number of subjects: 49
Study 18357655 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 49
Study 17042148 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of inhaled budesonide + 5 mg oral montelukast
Number of subjects: 71
Study 17042148 — intervention group
Group type: COMPARATOR
Intervention: 400 microg of inhaled budesonide
Number of subjects: 71
Study 12707491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous valproate loading
Number of subjects: 18
Study 12707491 — intervention group
Group type: COMPARATOR
Intervention: Oral valproate loading
Number of subjects: 18
Study 10714048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (5-40 mg/day)
Number of subjects: 28
Study 10714048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28